Evaluation and Management of Gross Hematuria

Initial Clinical Assessment

The American College of Radiology recommends that all patients with gross hematuria undergo urgent urologic evaluation with cystoscopy and upper tract imaging, as the malignancy risk is 30-40% regardless of other risk factors 1
A detailed smoking history with pack-year quantification is essential, as >30 pack-years is considered high risk for urothelial malignancy 3
Occupational or environmental exposures to chemicals, dyes, or carcinogens associated with bladder cancer should be assessed 1, 3
Family history of urologic malignancies and genetic risk factors should be evaluated 3
Blood pressure measurement is necessary to assess for renal parenchymal disease 3
Age and sex are important factors, as men >60 years and women >60 years have a higher malignancy risk 3
Irritative voiding symptoms, history of pelvic irradiation, chronic UTI, or indwelling catheters should be investigated 1

Urinalysis with microscopy is necessary to confirm true hematuria (not myoglobinuria or hemoglobinuria) 2
Serum creatinine should be measured to assess renal function and identify potential medical renal disease 3, 4
Urine culture is recommended if infection is suspected, and should be obtained before antibiotics if possible 2
Urine cytology may be considered, particularly in high-risk patients 2

Dysmorphic RBCs >80% and red cell casts suggest glomerular bleeding, characterized by tea-colored urine 1, 2
Significant proteinuria indicates renal parenchymal disease requiring nephrology referral 2, 4
Normal RBCs >80% without casts or proteinuria suggests a urologic source 2

CT urography (multiphasic) is the preferred imaging modality for upper tract evaluation in non-glomerular gross hematuria 1, 4
Cystoscopy is mandatory for lower tract evaluation to exclude bladder malignancy 1, 2
Both procedures should be performed urgently, even if bleeding is self-limited 2

Gross hematuria should never be dismissed as benign, even in patients on anticoagulation, as these medications unmask underlying pathology but do not cause hematuria 2
Evaluation should not be delayed for self-limited episodes, as 30-40% harbor malignancy 1, 2
Urinary tract infection should be excluded before attributing hematuria to infection alone, as malignancy can coexist 2
Vigorous exercise or menstruation should not be accepted as explanations for gross hematuria without complete evaluation 2

Smoking cessation counseling should be provided at the initial visit, with referral to evidence-based cessation programs 3
Patients with BPH still require full evaluation, as this does not exclude concurrent malignancy 2
Renal parenchymal disease is the most common benign nephrogenic cause but must be distinguished from malignancy 1